Rigvir® for Sale: Getting Qualified for Virotherapy Within Three Days
Cancer is insidious. It can escape after a full course of chemo or radio and then show up again. This is what makes most patients search for treatment alternatives to be used in addition to conventional medicine or independently.
And Rigvir® is one of these options for you to consider. It is the first non-genetically modified oncolytic virus able to recognize healthy and cancer-affected cells and kill the malicious disease without doing harm to surrounding tissues.
The medication was discovered back in 1960-70s by the team of Aina Muceniece, a Latvian scientist and immunologist. The virus was stemmed from the digestive kid system and passed a series of clinical trials (in 1968) to prove its significant therapeutic power. The medication was patented in 2002and registered in 2004 by the state authorities of Latvia as the major melanoma treatment.
It does not mean however that Rigvir® is accessible to the Latvian patients only. It can be shipped overseas too. Rigvir® availability details, effects, and treatment costs are described in the next few passages.
If you decided to start or keep on administering Rigvir® for cancer treatment, knowing your options can help you make the right choices.
Rigvir® Effects and Countries It Can Be Shipped to for Remote Treatment
One of the widespread questions about Rigvir® is that of how it works. As said before, the virus occurs naturally and has oncotropic and oncolytic effects. That is to say, Rigvir® identifies cancer cells in a human body and then replicates inside them destroying the tumor from within.
Rigvir® stimulates immune system to resist cancer and causes no harm to healthy tissues. The medication does not reproduce itself with time. Neither does it lead to addictiveness, which is safe for your health.
The only side-effects noted so far include slightly feverish temperature (up to 99.5°F/37.5°C) and fatigue during the first three days of the treatment.
As for the care options available, the patients eligible for the Rigvir® therapy can get treated both in Latvia and remotely, in their home cities, since the Rigvir® vials can be delivered worldwide including the US and UK, Canada, New Zealand, Australia, and more.
Latvia is the place where oncolytic virus was first found and tested. The medical staff working there has decades of experience (since 1960s). They know how to deal with complex cases and conduct trainings for immunologists and oncologists from abroad. If you wish to compare Mexico and Latvia, please read about Rigvir in Mexico.
Survival Rates for Cancer Patients After Rigvir® Therapy
The truth is, Rigvir® is not a cure-all. It is primarily prescribed to melanoma patients and, as it turned out, the drug proves effective in other limited number of cases.
Still, the medication can significantly prolong lives compared to the results obtained after going through chemo or radiotherapy. Though, each case should be examined individually for you to not be misled.
This is what we know about success rates of the Rigvir® therapy (as stated by Acta Medica Lituanica, a medical journal, in 2002):
- Melanoma patients treated with surgery had a 3-year survival rate in 46-58% of cases. The Rigvir® patients showed the same survival rate (3 years) in 57-84% of cases while 44-66% of patients had a 5-year survival rate.
- Ocular melanoma patients treated with Rigvir® had a 3-year survival rate in 90% of cases and a 5-year survival rate in 70% of cases.
- Patients with stage III stomach cancer had a 5-year survival rate after surgery only in 24-33% of cases. Whereas the patients who passed through a virotherapy complete course had the same survival rate in 47-60% of cases.
- 41-68% of patients with stage II-IV rectal cancer had a 5-year survival rate after surgery, while the patients treated with Rigvir® (having the same diagnosis) showed a 5-year survival rate in 71-78% of cases.
More information on Rigvir® success rates was also provided by APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica), a medical journal (July, 2016):
Before applying, you should consider the following requirements to become a successful candidate for Rigvir® treatment.
- You must be 18+ years old because the existing clinical experience in virotherapy for cancer is related to adults only.
- Your must have a confirmed oncological diagnosis because Rigvir® vaccine cannot be used as a preventative measure.
- You must have a solid tumor because there’s no clinical experience showing that Rigvir® can help fight liquid cancers such as lymphoma, myeloma, or leukemia.
You Can Buy Rigvir® Vials After Your Case is Examined by the Latvian Medical Board Within Three Days
Below you can find the list of diagnoses sensitive to virotherapy and medical documentation for an oncologist to review your case free of charge:
Once you provide your medical reports, the review of your case will take no longer than three business days and will be completed by a team of oncologists in Latvia - homeland to Rigvir®. You will get an email from the patient manager who will notify you whether or not you qualify for virotherapy. If yes, you can start booking your flight tickets to Latvia. If the assessment of your case shows you can't benefit from virotherapy, you’ll be informed immediately.
We are aware of how long it may take to request and wait for the files to be sent over to you. However, after you forward them for free case evaluation, it will take no longer than 72 hours to receive medical statement about whether you qualify for Rigvir® therapy along with other details about your treatment plan.
A patient is receiving Rigvir® injection
If the cancer specialists conclude you can benefit from virotherapy based on the medical files you provide, together with the medical statement you will receive details of the treatment package that best suits your health needs.
Please find more information on the basic treatment package below:
To get free evaluation of your case together with cost estimates please click the button below. We will get back to you within the first 24 hours but usually sooner.